Contrafect Corporation
- UEI
- LXUZL23QTTZ9
- CAGE
- 661G8
- SAM.gov registration
- Expired
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Website
- contrafect.com
- Founded
- 2008
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Research and development cost share contract to develop exebacase. | Office of the Assistant Secretary for Preparedness and Response | $16,381,940 |
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Entasis Therapeutics, Inc. | Waltham, MA | 325412 Pharmaceutical Preparation Manufacturing |
| Gangagen Biotechnologies Private LIMITED | Bengaluru, KA | — |
| Basilea Pharmaceutica International Ltd, Allschwil | Allschwil, BL | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Arietis Corporation | Boston, MA | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| Curza Inc. | Salt Lake City, UT | — |
About the company
Contrafect Corporation is a biotechnology company focused on discovering and developing therapeutic protein and antibody products for the treatment of infectious diseases, including those caused by drug resistant pathogens.
Through past prime federal contract awards, Contrafect Corporation has provided research and development services to develop Exebacase, a direct lytic agent to combat Staphylococcus aureus, under a $16.4 million cost-sharing contract with the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response. The contract aims to perform R&D activities over a two-year period concluding in July 2023 under the EXEBACASE: A Direct Lytic Agent to Combat S. aureus program.
Through past prime and sub federal grant awards, Contrafect Corporation has provided research and development services for novel antimicrobial therapies using recombinant lysin proteins to target microbial pathogens. This includes an IND enabling development project grant from the Defense Health Agency worth $7.2 million to develop CF-296, a lysin for the treatment of invasive Staphylococcus aureus infections. Contrafect Corporation has also received subawards as a subcontractor to the Trustees of Boston University, providing early stage research to develop treatments for respiratory infections caused by Pseudomonas aeruginosa and to advance development of a new class of phage-derived lytic agents called amurins with activity against multidrug resistant Gram-negative pathogens.
Quick answers
Is Contrafect Corporation registered in SAM.gov?
Contrafect Corporation's SAM.gov registration expired on October 31, 2024.
What is Contrafect Corporation's most recent federal award?
Contrafect Corporation's most recent federal contract award is Research and development cost share contract to develop exebacase (75A50121C00021), from Office of the Assistant Secretary for Preparedness and Response, on March 15, 2021.
On GovTribe
See Contrafect Corporation's full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors